Skip to main content
Signal8

NRX Pharmaceuticals, Inc. (NRXP)

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

NRx Pharmaceuticals, Inc. logo

NRx Pharmaceuticals, Inc.

NASDAQ:NRXPHealthcare
AH+0.38%$2.39
Close$2.38+0.00%
Mkt Cap$103.04M
Float41.51M
O/S43.3M
VOL877K sh
$ Vol$2.09M
RVOL0.51×
Inst Own28.1%
SI24.0%
Dilution
NRx Pharmaceuticals, Inc. logoNASDAQ:NRXPAH$2.39+0.38%
FormDescription
DEFA14A
Additional Proxy Materials
DEF 14A
Definitive Proxy Statement
3
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
8-K
7.01,9.01
3
8-K
8.01,9.01
1
8-K
1.01,9.01
3
8-K
8.01,9.01
3
8-K
7.01,9.01
8-K
2.02,9.01
5
10-Q
Quarterly Report
8
8-K
7.01
3
8-K
8.01
1
8-K
1.01,8.01,9.01
3
424B5
Prospectus Supplement
4
8-K
8.01,9.01
3
424B5
Prospectus Supplement
5
25-NSE
SEC Filing
10-Q
Quarterly Report
6
13G/A
Beneficial Ownership Report (Amended)
8-K
5.02,5.07,9.01
10-K
Annual Report
DEFA14A
Additional Proxy Materials
ARS
SEC Filing
DEF 14A
Definitive Proxy Statement

1-25 of 479

…

Recent SEC filings with analysis